| 生物活性 | |||
|---|---|---|---|
| 靶点 | 
 | ||
| 描述 | KG-501 is a CREB inhibitor, with an IC50 of 6.89 μM[1]. KG-501 disrupts phospho (Ser-133) CREB binding to KIX with a Ki of ~90 μM, using concentrations of CREB that are within the linear range of the binding assay. Treatment of HEK293T cells with KG-501 also blocks induction of endogenous CREB target genes (NR4A2, αCG, c-fos, and RGS2) by forskolin, indicating that KG-501 likely exerts a general effect on CREB activity[2]. In addition, KG-501 and CREB knockdown significantly decreased the levels of phosphorylated Akt, leading to a reduced number of oocytes with Foxo3a nuclear export. KG-501 also inhibited bpV (HOpic)-stimulated primordial follicle activation[3]. At 10 μM, KG-501 suppresses the expression of all of the IL-1β-induced CXC chemokine genes except CXCL8. For the protein level, KG-501 significantly suppresses IL-1β-induced CXCL5 protein secretion[4]. BAA (Bulleyaconitine) treatment induced phosphorylation of CREB (rather than NF-κB) and prodynorphin expression in cultured primary microglia, and antiallodynia in neuropathy, which were totally inhibited by the CREB inhibitor KG-501[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
| 1 mM 5 mM 10 mM | 2.65mL 0.53mL 0.26mL | 13.24mL 2.65mL 1.32mL | 26.47mL 5.29mL 2.65mL | 
| 参考文献 | 
|---|